Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Literature
1.
Mella-Abarca W, Barraza-Sánchez V, Ramírez-Parada K (2020) Model of telerehabilitation for people with breast cancer during the COVID-19 pandemic in Chile. ecancer 14:1085CrossRef
2.
Green BN, Pence TV, Kwan L, Rokicki-Parashar J (2020) Rapid deployment of chiropractic telehealth at 2 worksite health centers in response to the COVID-19 pandemic: observations from the field. J Manipulative Physiol Ther S0161–4754(20):30129–30139
3.
Akkaya N, Akkaya S, Gungor HR, Yaşar G, Atalay NS, Sahin F (2017) Effects of weighted and un-weighted pendulum exercises on ultrasonographic acromiohumeral distance in patients with subacromial impingement syndrome. J Back Musculoskelet Rehabil 30(2):221–228CrossRef
4.
de Rezende LF, Franco RL, de Rezende MF, Beletti PO, Morais SS, Gurgel MS (2006) Two exercise schemes in postoperative breast cancer: comparison of effects on shoulder movement and lymphatic disturbance. Tumori 92(1):55–61CrossRef
5.
Jiménez-Pavón D, Carbonell-Baeza A, Lavie CJ (2020) Physical exercise as therapy to fight against the mental and physical consequences of COVID-19 quarantine: Special focus in older people. Prog Cardiovasc Dis 63(3):386–388CrossRef
Metadata
Title
Telerehabilitation for patients with breast cancer through the COVID-19 pandemic
Authors
Laura Ferreira de Rezende
Vinícius Emanoel Francisco
Ricardo Laier Franco
Publication date
01-01-2021
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2021
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-05926-6

Other articles of this Issue 1/2021

Breast Cancer Research and Treatment 1/2021 Go to the issue

Epidemiology

Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study

Clinical trial

A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer

Clinical trial

Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer

Clinical trial

Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer

Preclinical study

Metformin and an insulin/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer

Review

Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits